Sitagliptin/simvastatin
Overview
Sitagliptin/simvastatin, sold under the brand name Juvisync, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes and hypercholesterolemia. It contains sitagliptin and simvastatin. Sitagliptin is a dipeptidyl peptidase-4 inhibitor and simvastatin is an HMG-CoA reductase inhibitor. These two disorders commonly occur in people at the same time, and have been typically treated with administration of these medications separately. The combination was approved in 2011, and sold under the brand name Juvisync by Merck. Juvisync was later removed from the market in 2013, due to business reasons.[1]
Interactions
Drug interactions
Juvisync should not be used with: strong CYP3A4 inhibitors, cyclosporine, danazol, gemfibrozil, and other fibrates. Caution should be used and the patient should be monitored if they are taking the following: amiodarone, dronedarone, ranolazine, calcium channel blockers, niacin, digoxin, coumarin anticoagulants, and colchicine.[3] WP
History
History
In 1991, Merck & Co's simvastatin was approved as an HMG-COA inhibitor to lower the levels of LDL cholesterol. In 2006, Merck & Co's sitagliptin was approved by the FDA for treatment of diabetes mellitus type 2.[4] WP⚠ Wikipedia itself has flagged this text: citation needed.
Legal status
Regulation
Juvisync was the first product to combine a cholesterol lowering drug with a type 2 diabetes drug in the same tablet.[5] WP
Chemistry
Harm reduction information
No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.
User reports
Erowid erowid.org
ListingsBluelight bluelight.org
ListingsReddit reddit.com
ListingsPop culture
No references added yet.
Add a reference
Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.
Opens when accounts launch.
Sources
- Other FDA Approves Juvisync, Combination of Sitagliptin and Simvastatin. October 7, 2011
- Journal / agency U.S. Food and Drug Administration. Drugs to be Discontinued
- Other RxList: The Internet drug Index. Juvisync Indications & Dosage
- Journal / agency Alvey L. FDA Approves New Treatment for Diabetes: First in a New Class of Diabetes Drugs. 2006-10-17
- Journal / agency Liscinsky, Morgan. FDA Approves Combination Therapy Juvisync. 2011-10-07
Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.